The recent approval of human papillomavirus (HPV) vaccine means that decision makers
need information beyond that available from randomized clinical trials to recommend …

Introduction: Human papillomavirus (HPV) is one of the world's most common sexually
transmitted infections, and has been associated with a number of cervical and non-cervical …

Recommendations for worldwide use of human papillomavirus (HPV) vaccine are
increasing. This study conducted a systematic review of articles related to cost-effectiveness …

Abstract Background In the Netherlands, low cervical cancer incidence and mortality rates
might limit the cost-effectiveness of vaccination against the human papillomavirus (HPV). We …

Background Due to the arrival of multi-valent HPV vaccines, it is more and more important to
have a better understanding of the relationship between vaccination and screening …

Background: The development of human papillomavirus (HPV)-related diseases is not
understood perfectly and uncertainties associated with commonly utilized probabilistic …

The human papilloma virus (HPV) vaccine is a new and expensive vaccine potentially
effective in the prevention of a cancer. We reviewed the economic evaluations (EEs) on the …

Background: With promising efficacy results from randomized control trials of human
papillomavirus (HPV) vaccines and the availability of new screening paradigms …

Background: Cervical cancer is a leading cause of death worldwide, and in Ireland it is the
ninth most commonly diagnosed cancer in women. Almost 100% of these cancers are …

Abstract The World Health Organization recommends establishing that human
papillomavirus vaccination is cost-effective before vaccine introduction. We searched …